slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
220,561-220,590 of 319,975
10
The chart uses a horizontal bar format to represent the development stage of each program.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
11
The diagram is a concentric circle model representing the layers of value in collaborations.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations Beat · Business Model1 hit
12
The slide uses a stepped arrow diagram to show progression from known targets to challenging novel targets.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
13
Includes footnote regarding fixed term bank deposits and currency basis.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
14
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
15
The slide uses a complex flow diagram combining a linear process with two internal feedback loops (Active Learning).Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
16
The slide uses a circular process flow to represent a proprietary R&D pipeline.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
17
The slide uses a process flow diagram to illustrate a clinical success story.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
18
The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
19
The slide uses a horizontal process-like layout to showcase four distinct technical pillars.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
20
The slide uses a circular flow diagram to represent the integration of AI and experimental biology.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
21
The diagram illustrates a flywheel-like process of data integration leading to novel targets.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
22
The slide uses a hierarchical clustering heatmap (dendrograms on top and left) to visualize drug sensitivity across 80 small molecules.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
23
The slide illustrates a computational drug discovery workflow using MPO (Multiparameter Optimisation).Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
24
The diagram uses a hub-and-spoke model to show data integration, followed by a funnel for molecule generation and a circular feedback loop for active learning.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
25
The slide features a 3D molecular model and a UI overlay showing various drug discovery metrics like potency, selectivity, and toxicity.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
26
The scatter plot highlights a specific cluster of 'active learning' selections that deviate from the standard Pareto frontier.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
27
The slide uses a small multiples approach to show dose-response curves across multiple patient samples, followed by a summary plot comparing the two groups over time.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
28
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
29
Exscientia | Investor Presentation Deck | 76 slidesExscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
30
The slide uses a molecular visualization as a background element to emphasize the drug's mechanism of action.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
31
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
32
The slide uses a human anatomy diagram to map specific cancer types to their respective organs, totaling approximately 75,000 patients annually.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
33
Includes a biological pathway diagram and a honeycomb diagram for indications.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
34
The slide uses a three-column layout to define technical constraints for drug development.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
35
The table uses a color-coded heatmap to indicate performance against criteria.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
36
The slide presents preclinical efficacy data for a CDK7 inhibitor ('617) in ovarian (OVCAR3) and triple-negative breast cancer (HCC70) models.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
37
The chart is a waterfall plot showing drug response scores across many patient samples, color-coded by diagnosis.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
38
The slide uses a heatmap to correlate '617 sensitivity with synergy outcomes for three different drug combinations.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
39
Venn diagram shows overlap of gene modulation; line charts show dose-response for POLR2A and HNRNPDL.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit